On April 10, 2026, Health Canada published its Final notice: Classification of topical products containing human-derived exosomes, human extracellular vesicles, or human cell-conditioned media, clarifying how these products are assessed at the cosmetic-drug interface. Under the clarified Health Canada exosome regulation approach, human-derived exosomes, human extracellular vesicles (EVs), and human cell-conditioned media are not considered “inherent drugs” based on the evidence currently available. However, this does not mean that products containing these ingredients are automatically cosmetics. A topical product may be regulated as either a drug or a cosmetic, depending on its representation, level of action, and composition.
Health Canada dated the final notice April 10, 2026. The notice does not specify a separate effective date or transition period. Companies developing or marketing these products in Canada should therefore determine the appropriate product classification under the existing Food and Drugs Act and applicable regulations.
What the Final Notice Clarifies
Health Canada first published a consultation notice on August 14, 2025, seeking feedback on the classification and regulation of topical products containing:
human-derived exosomes;
human extracellular vesicles; and
human cell-conditioned media.
After reviewing 16 responses from industry, industry associations, health care professional associations and other health partners, and interested members of the public, Health Canada issued the final notice on April 10, 2026.
The final position distinguishes these ingredients from substances that Health Canada considers inherent drugs. An inherent drug has intrinsic properties that leave it with no use other than as a drug, with tretinoin and corticosteroids cited by Health Canada as examples. By contrast, Health Canada states that, based on the evidence available to date, human-derived exosomes, human extracellular vesicles, and human cell-conditioned media are not inherent drugs and therefore have the potential to be used in either drug products or cosmetic products.
This distinction should not be interpreted as a general authorization of human-derived exosome cosmetics. Health Canada determines the regulatory status of the finished product, not solely the regulatory character of an individual ingredient.
A topical product containing these materials may be regulated as:
a drug product under the Food and Drugs Act, subject to the Food and Drug Regulations; or
a cosmetic product under the Food and Drugs Act, subject to the Cosmetic Regulations.
For the broader criteria Health Canada applies to borderline products, companies may also refer to the official Guidance Document: Classification of Products at the Cosmetic-Drug Interface.
Health Canada also notes that classification decisions are based on the evidence available at a particular point in time and may change if new scientific evidence or other relevant information becomes available.
How Health Canada Exosome Regulation Applies to Cosmetic vs. Drug Classification
Health Canada identifies three key considerations when classifying topical products containing human-derived exosomes, EVs, or human cell-conditioned media: product representation, level of action, and composition.
1. Product Representation and Claims
“Representation” covers more than the wording on the immediate product label. Health Canada considers:
indications for use;
package inserts;
advertisements;
label claims; and
explicit or implied representations made through words, images, symbols, or other communications.
A product falls within the drug framework if it is sold, manufactured, or represented for use in treating, diagnosing, preventing, or mitigating a disease, disorder, or abnormal physical state, or in restoring, correcting, or modifying organic functions in human beings. Products represented as providing therapeutic, pharmacological, or biological effects may therefore be classified as drugs rather than cosmetics.
For manufacturers and brands, this makes the overall claims strategy an important part of the classification assessment. Product names, website content, advertising materials, professional-use instructions, and other promotional communications should be reviewed together rather than assessing individual claims in isolation.
2. Level of Action and Method of Administration
The intended level of action is particularly important for exosome-based topical products.
Health Canada states that, to be classified as a cosmetic under the Food and Drugs Act, topical products containing human-derived exosomes, human extracellular vesicles, or human cell-conditioned media must show a lack of percutaneous absorption. Health Canada also states that such products should not need to be systemically absorbed to achieve their intended effect when used according to the manufacturer's instructions.
The distinction between these two formulations is important: the final notice uses “must” in relation to a lack of percutaneous absorption and “should not” in relation to the need for systemic absorption.
Health Canada acknowledges that cosmetics may exert a negligible organic effect that is local and transient. Cosmetics are normally applied to an external part of the body and do not need to be absorbed below the skin to achieve their intended cosmetic effect.
A product is not consistent with cosmetic classification if the manufacturer represents it for administration in a manner that facilitates percutaneous absorption. Health Canada specifically identifies microneedling and injection as examples. Products administered by injection are not considered cosmetics, with the statutory exception identified by Health Canada for tattoo ink.
This point is particularly relevant to products intended for use together with aesthetic procedures or delivery technologies designed to increase skin penetration.
3. Product Composition
Classification also depends on the composition of the finished product.
Under the Food and Drugs Act, a product falls within the definition of a drug where its composition indicates that it is an agent for:
treating, diagnosing, preventing, or mitigating a disease, disorder, or abnormal physical state; or
restoring, correcting, or modifying organic functions in human beings.
Health Canada further states that products exhibiting therapeutic or pharmacological activity are not considered cosmetics.
Companies should therefore assess the complete formulation rather than determining regulatory status solely on the basis of the presence of exosomes or other extracellular-vesicle-related ingredients. For companies developing exosome-based cosmetic ingredients for multiple markets, ingredient identity and nomenclature may also need to be considered alongside product classification. For further background, see REACH24H's Global Compliance Guide to INCI Registration for Exosome Ingredients.
Health Canada also clarifies that topical products containing exosomes, extracellular vesicles, or conditioned media from non-human sources may similarly be classified as either drugs or cosmetics. The same product-specific factors—representation, level of action, and composition—apply.
Under the current Food and Drugs Act, natural health products are considered a subset of drugs and are regulated under the Natural Health Products Regulations. Health Canada specifies that the term “drug” in this final notice includes natural health products, but the notice is not intended to determine whether a product classified as a drug should be further classified as a natural health product.
Human-Origin Ingredients May Trigger Additional Cosmetic Requirements
Classification as a cosmetic does not, by itself, mean that a human-derived ingredient can be treated in the same way as an unrestricted conventional cosmetic ingredient.
Health Canada's Cosmetic Ingredient Hotlist includes “Human origin, substance of” in its List of Ingredients that are Restricted for Use in Cosmetic Products. For substances falling within this entry, manufacturers using substances of human origin must provide Health Canada with:
the source of the substance;
a description of the method of production;
quality control data, particularly information relating to microbial limits, including viruses, and the absence of estrogenic substances; and
product labelling.
The current Hotlist entry does not specify a maximum permitted concentration for “Human origin, substance of”; instead, it establishes the above information requirements.
As a related ingredient compliance consideration, companies developing exosome-based cosmetic ingredients may also need to assess whether an appropriate INCI name is available for ingredient identification and labelling. REACH24H provides INCI Name Application support for companies seeking an INCI name for new cosmetic ingredients.
Health Canada identifies several potential health concerns associated with products containing human-derived exosomes, extracellular vesicles, or conditioned media, including potential toxic effects, unsubstantiated therapeutic claims for unauthorized drug products, and risks associated with materials of human origin, particularly the transmission of infectious diseases and adventitious agents.
Companies should also distinguish cosmetic notification from regulatory approval. Under section 30 of the Cosmetic Regulations, manufacturers and importers must notify Health Canada within 10 days after they first sell a cosmetic in Canada. Health Canada's Guide for Cosmetic Notifications provides further guidance on the notification process.
Submission of a cosmetic notification does not constitute:
approval for sale;
Health Canada's agreement that the product is correctly classified as a cosmetic; or
confirmation that the product complies with all applicable legislative requirements.
The regulated party remains responsible for ensuring compliance with the Food and Drugs Act, the Cosmetic Regulations, and any other applicable Canadian requirements.
For a broader overview of ingredient, notification, labelling, and market-entry requirements, companies can also review REACH24H's Canada Cosmetics Regulatory Compliance Guide.
For products classified as drugs, Health Canada states that authorization is required before sale. The appropriate authorization requirements depend on the applicable drug regulatory pathway and product classification.
Impact & Actionable Advice for Global Companies
The final notice provides greater clarity for companies evaluating exosome cosmetics regulation in Canada, but it does not establish a blanket cosmetic status for products containing human-derived exosomes, extracellular vesicles, or human cell-conditioned media.
For manufacturers, ingredient suppliers, brand owners, and exporters planning Canadian market entry, REACH24H recommends conducting a product-specific assessment before commercialization. In particular, companies should:
Assess classification at the finished-product level. Review representation, intended purpose, level of action, composition, and method of administration together rather than relying on the product name or cosmetic positioning.
Review all product representations. Evaluate labels, websites, advertisements, package inserts, instructions for use, and other explicit or implied claims against Canada's cosmetic-drug classification criteria.
Evaluate absorption and administration. Determine whether the intended effect depends on percutaneous or systemic absorption and whether the product is represented for use with microneedling, injection, or another method that facilitates skin penetration.
Review the complete formulation. Confirm that the product composition does not indicate therapeutic or pharmacological activity that would be inconsistent with cosmetic classification.
Determine whether human-origin Hotlist requirements apply. Where the relevant ingredient falls within the “Human origin, substance of” entry, prepare the required sourcing, production, quality-control, and labelling information.
Plan the appropriate Canadian regulatory pathway before launch. Cosmetic products remain subject to notification and other applicable cosmetic requirements, while products classified as drugs require the applicable Health Canada authorization before sale.
Companies operating internationally should also avoid applying the regulatory status assigned in one jurisdiction directly to another market. Exosomes and other human-derived biological materials are subject to different regulatory approaches across jurisdictions, making market-specific classification and compliance assessment essential. Companies also targeting the United States can review REACH24H's analysis of exosome-based ingredients and their regulatory status in the U.S. market to understand how the regulatory approach differs from Canada.
How REACH24H Can Help
Products containing human-derived exosomes, extracellular vesicles, and human cell-conditioned media may raise overlapping questions involving product classification, ingredient compliance, claims, safety documentation, and market-entry requirements.
REACH24H can support companies with:
Canada cosmetic-drug classification assessments for exosome and other biotechnology-based topical products;
review of formulations against the Cosmetic Ingredient Hotlist and other applicable ingredient requirements;
claims, labelling, intended-use, and administration-method reviews;
assessment of human-origin ingredient documentation and identification of potential data gaps;
support with applicable Canadian cosmetic notification and market-entry requirements; and
regulatory pathway assessment where a product may fall outside the cosmetic framework.
Planning to market a topical product containing human-derived exosomes, extracellular vesicles, or human cell-conditioned media in Canada? An early classification and compliance review can help identify potential regulatory issues before commercialization.
